NASDAQ · Biotechnology

Maze Therapeutics, Inc. (MAZE) Stock

$25.88 -1.41% NASDAQ: MAZE Healthcare

Valuation

MetricValue
Price$25.88
Market Cap$1.43B
P/E Ratio-9.65
P/B Ratio3.44
P/S Ratio73.14
EPS (TTM)$-3.05
52-Week High$53.65
52-Week Low$21.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-34.94%
ROA-25.13%
ROCE-28.63%
Gross Margin92.04%
Operating Margin-6.70%
Net Margin-667.95%
Debt/Equity0.13
Current Ratio15.22

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$168.0M$0
Operating Profit$-111.0M$-99.0M$58.0M$-143.0M
Net Profit$-115.0M$-100.0M$52.0M$-131.0M
EPS$-2.63$-2.29$0.08$-3.05
Op Margin——34.4%—

Balance Sheet (USD)

Metric2022202320242025
Total Assets$150.0M$72.0M$241.0M$397.0M
Total Liabilities$49.0M$61.0M$44.0M$42.0M
Cash$100.0M$29.0M$197.0M$189.0M
Borrowings$32.0M$50.0M$27.0M$23.0M

Latest News

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? Motley Fool · Jun 29, 2026 Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk Simply Wall St. · Jun 13, 2026 Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now Insider Monkey · Jun 8, 2026 Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? Motley Fool · Jun 5, 2026 Maze Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-99.0M$-87.0M$76.0M$-112.0M
Investing Cash Flow$-5.0M$-1.0M$-2.0M$-172.0M
Financing Cash Flow$0$0$0$0
Net Cash Flow$-101.0M$-71.0M$168.0M$-8.0M
Free Cash Flow$-101.0M$-87.0M$75.0M$-113.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.18
EV / EBITDA-10.14
FCF Yield-7.30%
Quick Ratio18.31
Interest Coverage-81.03
Return 1Y56.97%
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.46%
Institutions Held95.12%
Institutions Float Held96.54%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 4,567,2742026-03-31
TRV GP IV, LLC4,473,9582026-03-31
Arch Venture Management, Llc4,120,0532026-03-31
Deep Track Capital, Lp3,477,5622026-03-31
Janus Henderson Group PLC2,858,8762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is led by CEO Jason V. Coloma, publicly traded since 2025.

Maze Therapeutics, Inc. (MAZE) stock trades at $25.88 with a market capitalization of $1.43B. The stock is valued at a price-to-earnings (P/E) ratio of -9.65, price-to-book of 3.44, price-to-sales of 73.14. Over the past 52 weeks the stock has ranged between $21.95 and $53.65, and currently trades 51.8% below its 52-week high.

On profitability, Maze Therapeutics, Inc. generates a return on equity (ROE) of -34.94%, return on capital employed of -28.63%, an operating margin of -6.70%, a net profit margin of -667.95%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides